| 引用本文: | 付洁,吴斌.阿法替尼在EGFR突变的晚期非小细胞肺癌患者治疗中的预算影响分析[J].中国现代应用药学,2019,36(6):723-725. |
| FU Jie,WU Bin.Budget Impact Analysis of Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation[J].Chin J Mod Appl Pharm(中国现代应用药学),2019,36(6):723-725. |
|
| 摘要: |
| 目的 在EGFR突变的晚期非小细胞肺癌患者的治疗中，通过评估阿法替尼（Giotrif®）纳入中国医保报销系统将对社会总治疗费用产生的影响，为医疗保险部门提供决策依据。方法 构建预算影响分析模型，评估将阿法替尼纳入中国医保报销系统后3年（2018-2020年）对医保预算的影响。结果 阿法替尼纳入医保之前与纳入之后相比，3年内医保支付将分别减少3 644，6 632，9 620万元，3年总治疗费用支出将减少19 896万元。结论 该分析预计，将阿法替尼纳入中国医疗报销系统用于EGFR突变的晚期非小细胞肺癌患者的治疗，将降低医保总支出。 |
| 关键词: 肺癌 EGFR突变 预算影响 阿法替尼 中国 |
| DOI：10.13748/j.cnki.issn1007-7693.2019.06.016 |
| 分类号:R956 |
| 基金项目:第四轮公共卫生三年行动计划重点学科建设项目（15GWZK0901） |
|
| Budget Impact Analysis of Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation |
|
FU Jie, WU Bin
|
|
Medical Decision and Economic Group, Department of Pharmacy, Southern Campus, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200112, China
|
| Abstract: |
| OBJECTIVE To evaluate the impact on total social costs for non-small cell lung cancer(NSCLC) patients with EGFR-mutation through a budget impact analysis, comparing the treatment strategy with and without afatinib(Giotrif®) in the Chinese national reimbursement system, which would provide evidence for medical insurance decision makers. METHODS The budget impact model was constructed to assess the health care budgets changes in the 3 years (2018-2020) after afatinib was listed in Chinese national reimbursement system. RESULTS Compared with afatinib wasn't listed in health care system, total health care budgets in 3 years after afatinib was listed in would decrease by 36.44, 66.32, 96.20 million RMB, respectively. It would save 198.96 million RMB among 3 years. CONCLUSION The analysis suggests that the adoption of afatinib in the Chinese health care reimbursement list for the treatment of advanced NSCLC patients with EGFR-mutation will reduce the health care expenditure. |
| Key words: lung cancer EGFR-mutation budget impact afatinib China |
